Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade

Documenti analoghi

• Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
  di: Wali, Vikram B., et al.
  Pubblicazione: (2019)
• Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome
  di: Powles, Ryan L., et al.
  Pubblicazione: (2020)
• Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
  di: Xiaotong Li, et al.
  Pubblicazione: (2019-04-01)
• Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
  di: Li, Xiaotong, et al.
  Pubblicazione: (2019)
• Immune microenvironment of triple-negative breast cancer in African American and Caucasian women
  di: O’Meara, Tess, et al.
  Pubblicazione: (2019)